The World Health Organization (WHO) has announced that it has added Bavarian Nordic’s mpox vaccine to its list of prequalified vaccines.
The decision is expected to facilitate timely and increased access to Imvanex (MVA-BN), which is now the first mpox vaccine to be prequalified by the organisation.
More than 120 countries have confirmed over 103,000 cases of mpox, a disease with symptoms similar to smallpox, since the onset of the global outbreak in 2022.
Originally developed as a smallpox vaccine in collaboration with the US government, Imvanex can be administered in individuals aged 18 years and over as a two-dose injection given four weeks apart, WHO said…
